Frontline treatment with chemoimmunotherapy for limited-stage ocular adnexal MALT lymphoma with adverse factors: a phase II study

Autor: Seok-Goo Cho, Hyo Jung Kim, Jee Ho Chang, Jae Wook Yang, Won-Sik Lee, Sung Yong Oh, Seong Kyu Park, Sung-Yong Kim, Deok-Hwan Yang, Min Joung Lee, Hee Bae Ahn, Suk-Woo Yang
Rok vydání: 2017
Předmět:
Zdroj: Oncotarget
ISSN: 1949-2553
DOI: 10.18632/oncotarget.19788
Popis: // Sung-Yong Kim 1 , Suk-Woo Yang 2 , Won-Sik Lee 3 , Jae Wook Yang 4 , Sung Yong Oh 5 , Hee Bae Ahn 6 , Deok-Hwan Yang 7 , Seong Kyu Park 8 , Jee Ho Chang 9 , Hyo Jung Kim 10 , Min Joung Lee 11 and Seok-Goo Cho 12 1 Department of Hematology-Oncology, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea 2 Department of Ophthalmology and Visual Science, Seoul St. Mary’s Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea 3 Department of Hematology and Oncology, Inje University College of Medicine, Busan Paik Hospital, Busan, Korea 4 Department of Ophthalmology, Busan Paik Hospital, Inje University, Busan, Korea 5 Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea 6 Department of Ophthalmology, Dong-A University College of Medicine, Busan, Korea 7 Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Jeollanamdo, Korea 8 Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University, Bucheon, Korea 9 Department of Ophthalmology, Soonchunhyang University Bucheon Hospital, Soonchunhyang University, Bucheon, Korea 10 Division of Hematology-Oncology, Department of Internal Medicine, College of Medicine, Hallym University, Hallym University Sacred Heart Hospital, Anyang, Korea 11 Department of Ophthalmology, College of Medicine, Hallym University, Hallym University Sacred Heart Hospital, Anyang, Korea 12 Department of Hematology, Catholic Blood and Marrow Transplantation Center, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea Correspondence to: Seok-Goo Cho, email: chosg@catholic.ac.kr Keywords: lymphoma, ocular, mucosa associated lymphoid tissue, rituximab, chemoimmunotherapy Received: March 09, 2017 Accepted: June 24, 2017 Published: August 02, 2017 ABSTRACT Background: Radiotherapy is a commonly used treatment for limited-stage ocular adnexal mucosa-associated lymphoid tissue lymphoma (OAML) but showed a substantial relapse risk if the disease involves beyond-conjunctiva or bilateral conjunctivae. Systemic chemoimmunotherapy may be an alternative frontline therapy for the limited disease with those adverse prognostic factors. Patients and methods: We designed a multicenter, phase II study of the chemoimmunotherapy, rituximab, cyclophosphamide, vincristine, and prednisolone (R-CVP) for the treatment of patients with limited-stage OAML with bilateral or beyond-conjunctival involvement. Thirty-three patients with Ann Arbor stage I OAML with the adverse factors were enrolled. Patients received six cycles of R-CVP followed by two cycles of rituximab therapy. Results: At the end of treatment, all the enrolled patients had responded. The cumulative complete response achievement was 93.9% at 2 years. At a median follow-up of 50.6 months, three patients had progressed. Progression-free survival and overall survival at 4 years was 90.3±5.3% and 100%, respectively. Conclusions: This phase II study demonstrated durable efficacy of R-CVP chemoimmunotherapy, which has promise as an alternative frontline therapy for the limited-stage OAML patients with adverse prognostic factors. Clinical trial registration: NCT01427114.
Databáze: OpenAIRE
Externí odkaz: